JG
HRTX icon

Jefferies Group’s Heron Therapeutics HRTX Stock Holding History

Jefferies Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-164,100
Closed -$939K – 1684
2022
Q1 		$939K Sell
164,100
-44,500
-21% -$326K 0.01% 899
2021
Q4 		$1.9M Buy
+208,600
New +$2.13M 0.01% 799
2020
Q2 		– Sell
-137,500
Closed -$1.61M – 1639
2020
Q1 		$1.61M Buy
+137,500
New +$2.58M 0.02% 787

Other funds holding HRTX

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Jefferies Group's HRTX Position: Q2 2022 in Review

Jefferies Group sold out of Heron Therapeutics (HRTX) in Q2 2022, closing a stake of 124,545 shares — an estimated $712K sold.

Jefferies Group first reported a position in HRTX in Q4 2017 and held it in 6 quarters. The position peaked at $2.37M in Q4 2021. 174 funds tracked by Wall St. Rank hold HRTX as of Q2 2022.

  • Jefferies Group reported no remaining Heron Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Jefferies Group sold 124,545 Heron Therapeutics shares in Q2 2022, an estimated $712K.
  • Jefferies Group first reported a position in Heron Therapeutics in Q4 2017 and held it in 6 quarters.
  • Jefferies Group's Heron Therapeutics position peaked at $2.37M in Q4 2021.
  • 174 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2022.

Based on Jefferies Group's 13F filing for Q2 2022, filed 15 Aug 2022.